Prevention of fibrosis progression in CCl 4-Treated rats: Role of the hepatic endocannabinoid and apelin systems

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 3, 2012, Pages 629-637

  Reichenbach, Vedrana ^a,b   Ros, Josefa ^a,b   Fernández Varo, Guillermo ^a,b,c   Casals, Gregori ^a   Melgar Lesmes, Pedro ^a,b   Campos, Teresa ^a   Makriyannis, Alexandros ^d   Morales Ruiz, Manuel ^a,b,c   Jiménez, Wladimiro ^a,b,c,e  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d NORTHEASTERN UNIVERSITY   (United States)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; ALPHA SMOOTH MUSCLE ACTIN; ANTIFIBROTIC AGENT; APELIN; APELIN 13; APELIN RECEPTOR; CANNABINOID 2 RECEPTOR; CASPASE 3; COLLAGEN; ENDOCANNABINOID; F 13A; MATRIX METALLOPROTEINASE; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVATION; GENE; GENE EXPRESSION REGULATION; LIVER FIBROSIS; LIVER PARENCHYMA; LIVER PROTECTION; MALE; MEAN ARTERIAL PRESSURE; MOLECULAR MECHANICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA GENE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SIGNAL TRANSDUCTION; TISSUE INHIBITOR OF MATRIX METALLOPROTEINASE 1 GENE;

ANIMALS; APOPTOSIS; BLOOD PRESSURE; CARBON TETRACHLORIDE; CASPASE 3; DISEASE PROGRESSION; ENDOCANNABINOIDS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB2; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, G-PROTEIN-COUPLED; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84857311013     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.188078     Document Type: Article

References (33)

1. Akhmetshina A, Dees C, Busch N, Beer J, Sarter K, Zwerina J, Zimmer A, Distler O, Schett G, and Distler JH (2009) The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum 60:1129-1136.
2. Arthur MJ (2000) Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 279:G245-G249.
3. Clària J and Jiménez W (1999) Renal dysfunction and ascites in carbon tetrachloride- induced cirrhosis in rats, in The Liver and the Kidney (Arroyo V, Schrier RW, Rodés J, and Ginès P eds) pp 379-396, Blackwell Science, Boston.
4. Daviaud D, Boucher J, Gesta S, Dray C, Guigne C, Quilliot D, Ayav A, Ziegler O, Carpene C, Saulnier-Blache JS, et al. (2006) TNF-α up-regulates apelin expression in human and mouse adipose tissue. FASEB J 20:1528-1530.
5. Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S, Nhieu JT, Belot MP, Zimmer A, Even P, et al. (2009) Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 4:e5844.
6. Friedman SL (2008) Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88:125-172.
7. Friedman SL (2010) Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 7:425-436.
8. Gressner OA, Weiskirchen R, and Gressner AM (2007) Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol 6:7.
9. Hézode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, Medkour F, Pawlostky JM, Lotersztajn S, and Mallat A (2008) Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 134:432-439. (Pubitemid 351173051)
10. Horváth B, Magid L, Mukhopadhyay P, Bátkai S, Rajesh M, Park O, Tanchian G, Gao RY, Goodfellow CE, Glass M, et al. (2011) A new cannabinoid 2 receptor agonist HU-910 attenuates oxidative stress, inflammation, and cell death associated with hepatic ischemia/reperfusion injury. Br J Pharmacol doi:10.1111/j. 1476- 5381.2011.01381.x.
11. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, et al. (2003) Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100:10529-10533. (Pubitemid 37071912)
12. Iredale JP (2007) Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117:539-548.
13. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Bátkai S, Mukhopadhyay P, Horiguchi N, Harvey-White J, Marsicano G, Lutz B, et al. (2008) Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 7:227-235. (Pubitemid 351285525)
14. Jimenez W, Parés A, Caballería J, Heredia D, Bruguera M, Torres M, Rojkind M, and Rodés J (1985) Measurement of fibrosis in needle liver biopsies: evaluation of a colorimetric method. Hepatology 5:815-818. (Pubitemid 15236626)
15. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A, and Lotersztajn S (2005) Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128:742-755. (Pubitemid 40585376)
16. Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, and O'Dowd BF (2005) Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 146:231-236. (Pubitemid 40051744)
17. Liu HY, Yang Q, Duan RX, Zhang YW, and Tang WX (2008) [Effects of anandamide on the activation and proliferation of hepatic stellate cells through cannabinoid-2 receptors]. Zhonghua Gan Zang Bing Za Zhi 16:430-434.
18. Malan TP Jr, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, Porreca F, and Makriyannis A (2001) CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93:239-245. (Pubitemid 32763181)
19. Marra F (1999) Hepatic stellate cells and the regulation of liver inflammation. J Hepatol 31:1120-1130.
20. Masri B, Morin N, Cornu M, Knibiehler B, and Audigier Y (2004) Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J 18:1909-1911. (Pubitemid 39602280)
21. Melgar-Lesmes P, Casals G, Pauta M, Ros J, Reichenbach V, Bataller R, Morales- Ruiz M, and Jimenez W (2010) Apelin mediates the induction of profibrogenic genes in human hepatic stellate cells. Endocrinology 151:5306-5314.
22. Melgar-Lesmes P, Pauta M, Reichenbach V, Casals G, Ros J, Bataller R, Morales- Ruiz M, and Jiménez W (2011) Hypoxia and proinflammatory factors upregulate apelin receptor expression in human stellate cells and hepatocytes. Gut 60:1404-1411.
23. Morales-Ruiz M and Jiménez W (2005) Neovascularization, angiogenesis, and vascular remodelling in portal hypertension, in Portal Hypertension: Pathobiology, Evaluation, and Treatment (Sanyal AJ, Shah VH eds) pp 99-112, Humana Press, Totowa, NJ.
24. Muñoz-Luque J, Ros J, Fernández-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, Friedman SL, Arroyo V, and Jiménez W (2008) Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 324:475-483.
25. Pacher P, Bátkai S, and Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462. (Pubitemid 44394908)
26. Pinzani M, Gesualdo L, Sabbah GM, and Abboud HE (1989) Effects of plateletderived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest 84:1786-1793. (Pubitemid 20016182)
27. Principe A, Melgar-Lesmes P, Fernández-Varo G, del Arbol LR, Ros J, Morales-Ruiz M, Bernardi M, Arroyo V, and Jiménez W (2008) The hepatic apelin system: a new therapeutic target for liver disease. Hepatology 48:1193-1201.
28. Reichenbach V, Ros J, and Jiménez W (2010) Endogenous cannabinoids in liver disease: many darts for a single target. Gastroenterol Hepatol 33:323-329.
29. Ros J, Fernández-Varo G, Muñoz-Luque J, Arroyo V, Rodés J, Gunnet JW, Demarest KT, and Jiménez W (2005) Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention. Br J Pharmacol 146:654-661. (Pubitemid 41573616)
30. Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, and Kunos G (2011) Endocannabinoids in liver disease. Hepatology 53:346-355.
31. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, Serriere- Lanneau V, Ledent C, Mallat A, and Lotersztajn S (2006) CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12:671-676. (Pubitemid 43865236)
32. Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodés J, Friedman SL, Carmeliet P, Jiménez W, and Morales-Ruiz M (2007) Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46:1919-1926.
33. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK, Hooker BA, Dart MJ, Sullivan JP, and Meyer MD (2006) In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 149:145-154. (Pubitemid 44360095)